Generate:Biomedicines, a pioneering force in the application of generative artificial intelligence (AI) in drug development, announced significant advancements in its clinical pipeline and expanded collaboration with Amgen at the 42nd Annual J.P. Morgan Healthcare Conference.
Clinical Breakthroughs and Strategic Collaborations
Mike Nally, CEO of Generate:Biomedicines and CEO-Partner at Flagship Pioneering, will present the company's strides in generative biology, emphasizing the dosing of the first patient in the GB-0895 study, advancements in the GB-0669 phase 1 study, and an expansion of their collaboration agreement with Amgen.
"In 2023, we made substantial advances in computational and experimental capabilities, shaping the future of generative biology," said Nally.
Key Hig
Generate:Biomedicines Spearheads the Future of Generative AI in Medicine at J.P. Morgan Healthcare Conference
- By 재은
- Published on
Generate:Biomedicines revolutionizes drug development with its groundbreaking clinical pipeline and expanded Amgen collaboration, leveraging generative AI to transform the future of medicine.
